Browse by category

The FDA has approved Wegovy (semaglutide) injection 2.4 mg to treat adults with MASH with moderate to advanced liver scarring (fibrosis),...

Endoscopic sleeve gastroplasty (ESG) may be an effective alternative therapy in the treatment of patients with metabolic...

D&D Pharmatech has completed patient enrolment in DD01-DN-2, an ongoing Phase 2 trial designed to evaluate the efficacy and safety of...

Results from part 1 of the ongoing Phase 3 ESSENCE trial - evaluating the effect of once-weekly subcutaneous semaglutide 2.4mg on liver...

The FDA has granted Breakthrough Therapy designation to Zealand Pharma’s survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist...

University of Massachusetts Medical School researchers have identified a novel pathway in the progression of metabolic liver disease that...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Results from Eli Lilly and Company’s SYNERGY-NASH that evaluated the investigational use of tirzepatide in adults with biopsy-proven...

Up to 83.0% of adults treated with survodutide (Boehringer Ingelheim and Zealand Pharma) achieved a statistically significant improvement...